Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
Plasma prolactin and fluphenazine concentrations were measured in a group of 17 patients (9 males, 8 females) with schizophrenia who were receiving chronic treatment with fluphenazine decanoate. Neither measure was significantly correlated with clinical effect, as measured by the Brief Psychiatric Rating Scale, at any of the 5 pre-injection times examined. None of the measures showed statistically significant (P greater than 0.05; MANOVA) variations with time. Neither measure showed a significant correlation with the dose (expressed as mg/kg) of fluphenazine. The implications of the study for monitoring chronic treatment of schizophrenia are discussed.
Norman
T R
TR
Department of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
Marriott
P F
PF
Kimber
N M
NM
Burrows
G D
GD
D000328:Adult; D005260:Female; D005476:Fluphenazine / Q000031:analogs & derivatives* / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*
D011388:Prolactin; C011825:fluphenazine depot; D005476:Fluphenazine